Aryx Therapeutics I Stock Net Asset
Aryx Therapeutics I fundamentals help investors to digest information that contributes to Aryx Therapeutics' financial success or failures. It also enables traders to predict the movement of Aryx Pink Sheet. The fundamental analysis module provides a way to measure Aryx Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aryx Therapeutics pink sheet.
Aryx |
Aryx Therapeutics I Company Net Asset Analysis
Aryx Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Aryx Therapeutics Net Asset | 12.41 M |
Most of Aryx Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aryx Therapeutics I is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Aryx Therapeutics I has a Net Asset of 12.41 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Aryx Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.Aryx Therapeutics is currently under evaluation in net asset category among its peers.
Aryx Fundamentals
| Return On Asset | -0.75 | ||||
| Current Valuation | 237.58 K | ||||
| Shares Outstanding | 33.46 M | ||||
| Shares Owned By Institutions | 0.14 % | ||||
| Number Of Shares Shorted | 89.05 K | ||||
| Price To Book | 37.83 X | ||||
| EBITDA | (14.18 M) | ||||
| Net Income | (33.17 M) | ||||
| Cash And Equivalents | 2.95 M | ||||
| Cash Per Share | 0.09 X | ||||
| Debt To Equity | (5.11) % | ||||
| Current Ratio | 0.47 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (34.97 M) | ||||
| Short Ratio | 0.79 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Target Price | 1.5 | ||||
| Number Of Employees | 56 | ||||
| Beta | 0.0896 | ||||
| Market Capitalization | 237.58 K | ||||
| Total Asset | 12.41 M | ||||
| Retained Earnings | (187.11 M) | ||||
| Working Capital | 126 K | ||||
| Current Asset | 8.62 M | ||||
| Current Liabilities | 8.49 M | ||||
| Z Score | -24.3 | ||||
| Net Asset | 12.41 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |